Short answer
PTC THERAPEUTICS, INC. (PTCT) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $358M (up 69.6% year over year) with net income of −$52M.
Q3 2026 key financials · XBRL
- Revenue
- $358M
- +69.6% YoY · −0.8% QoQ
- Net income
- −$52M
- −425.2% YoY · −161.9% QoQ
- Operating margin
- 7.0%
- EPS (diluted)
- −$0.56
- −450.0% YoY · −160.2% QoQ
Source: XBRL data from the PTC THERAPEUTICS, INC. (PTCT) Q3 2026 10-Q on SEC EDGAR. USD.
PTC THERAPEUTICS, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $357.8M, up from $210.2M YoY, driven by Sephience and Evrysdi royalties
- Sephience best performer: $181.9M sales vs $19.6M YoY; Emflaza worst, $25.1M vs $35.2M
- Net loss $0.1M implied by reported data, versus $0.1M net income YoY; no margin percentages disclosed
- Cash, equivalents and marketable securities $2.13B; operating cash flow $44.8M vs $745.5M
- $535.4M convertible-note proceeds, $328.8M used for 2026 note repurchases; headwinds from Emflaza generics and Translarna access risks
Risk Factors
- New regulatory risk: ST-920 acquisition adds FDA accelerated-approval uncertainty, with rolling BLA completion expected in fourth quarter 2026
- Most material update: Translarna U.S. development discontinued after NDA withdrawal in February 2026, while EEA authorization remains affected by the EC negative opinion
- Regulatory compliance risk: vatiquinone requires an additional controlled study after FDA’s August 2025 complete response letter
- Operational risk: three distributors each exceeded the undisclosed concentration threshold for net product sales in 2026
- Financial risk: $550.0 million 2031 Convertible Notes mature June 15, 2031, alongside $2,305.6 million royalty-sale liability carrying an 11.0% effective rate
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PTC THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.